

Record USA Sales for February 2024

Highlights

- **USA sales for the month of February 2024 of US\$0.99 million (unaudited) were a record. USA sales were 20% higher than January 2024 and 11% higher than October 2023, the previous record USA sales month.**
- **Sales revenue for the USA for the 2 months ended 29 February 2024 was US\$1.82m (unaudited) representing 65% sales growth compared with the prior comparative period (PCP).**
- **USA Sales for the 8 months to 29 February 2024 were US\$6.88 million (unaudited), up 64% on the sales for the PCP.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**) today announces that sales of its portfolio of glaucoma surgical devices in the USA were US\$6.88 million for the eight months to 29 February 2024 (unaudited). This represents growth of 64% over the sales in the USA on the PCP, measured in US dollars.

The strong performance during the period was driven by the US surgeon's take-up of *iTrack™ Advance* since its launch in May 2023. Since then, the Company has continued to receive excellent feedback on the product's performance from new and existing customers.

Sales in February 2024 were 20% higher than January 2024 and 11% higher than October 2023, the highest sales month prior to the announcements made by five Medicare Administrative Contractors (MACs) at the beginning of November 2023. These announcements proposed changes in reimbursement for minimally invasive glaucoma surgical procedures and caused uncertainty among customers that hindered sales in November and December of 2023.

As previously announced, the proposed changes were withdrawn by the MACs on 29 December 2023. The sales in January and February in the USA show evidence of normalisation of customer purchasing patterns following the uncertainty created by the MAC announcements.

Sales outside the USA were US\$0.36 million during January and February 2024 and were in line with the PCP.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Company

Kate Hunt
Chief Commercial Officer
+61 404 080 679
khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com